3 results
Approved WMOCompleted
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Approved WMOWill not start
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
Approved WMOCompleted
To determine the specificity of the effects of histamine H1-receptor blockade on different cognitive functions and processes.